ATE87659T1
(de)
|
1986-09-02 |
1993-04-15 |
Enzon Lab Inc |
Bindungsmolekuele mit einzelpolypeptidkette.
|
HUT53672A
(en)
|
1988-02-25 |
1990-11-28 |
Gen Hospital Corp |
Quick immunoselective cloning process
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
JPH06504186A
(ja)
|
1990-07-13 |
1994-05-19 |
ザ ジェネラル ホスピタル コーポレイション |
Cd53細胞表面抗原とその使用
|
ATE275198T1
(de)
|
1991-12-02 |
2004-09-15 |
Medical Res Council |
Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
|
JP3720353B2
(ja)
|
1992-12-04 |
2005-11-24 |
メディカル リサーチ カウンシル |
多価および多重特異性の結合タンパク質、それらの製造および使用
|
AU6123894A
(en)
|
1993-01-29 |
1994-08-15 |
Board Of Trustees Of The Leland Stanford Junior University |
Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
|
GB9424449D0
(en)
|
1994-12-02 |
1995-01-18 |
Wellcome Found |
Antibodies
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
JP4233608B2
(ja)
|
1996-10-15 |
2009-03-04 |
塩野義製薬株式会社 |
自己抗体測定方法
|
WO1998016254A1
(fr)
|
1996-10-17 |
1998-04-23 |
Immunomedics, Inc. |
Conjugue d'une toxine non antigenique et proteine de fusion d'un systeme recepteur de penetration intracellulaire
|
WO2000006194A2
(fr)
|
1997-02-05 |
2000-02-10 |
Biotransplant, Inc. |
Depletion de cellules responsables du rejet d'une greffe induit par des anticorps
|
JP3835827B2
(ja)
|
1997-05-02 |
2006-10-18 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ,アズ リプレゼンティッド バイ ザ セクレタリーオブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
悪性細胞に対する、oncタンパク質を含む、免疫毒素
|
JP2003524587A
(ja)
|
1998-06-05 |
2003-08-19 |
マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ |
多発性骨髄腫を処置するための、cd38に対する、遺伝子操作した抗体の使用
|
US7223397B1
(en)
|
1999-01-07 |
2007-05-29 |
Research Development Foundation |
Potentiation of anti-CD38-Immunotoxin cytotoxicity
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
DE60111498T2
(de)
|
2000-02-15 |
2006-05-11 |
Astellas Pharma Inc. |
Kondensierte imidazolderivate
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
EP1292334A4
(fr)
|
2000-06-22 |
2003-11-19 |
Idec Pharma Corp |
Proteine de fusion bispecifique et son procede d'utilisation permettant d'ameliorer l'action tueuse de cellules effectives sur des cellules cibles
|
EP1174440A1
(fr)
|
2000-07-19 |
2002-01-23 |
U-BISys B.V. |
Un épitope exprimé sélectivement sur la molécule humaine CD38 et détecté par un fragment d'un anticorps humain de forme scFv dérivé d'une librairie "phage display"
|
AU1331802A
(en)
|
2000-10-17 |
2002-04-29 |
Trudeau Inst Inc |
Cd38 modulated chemotaxis
|
US20070042436A1
(en)
|
2000-10-17 |
2007-02-22 |
Lund Frances E |
CD38 modulated chemotaxis
|
US20040166490A1
(en)
|
2002-12-17 |
2004-08-26 |
Morris David W. |
Novel therapeutic targets in cancer
|
NZ536746A
(en)
|
2002-06-13 |
2007-02-23 |
Crucell Holland Bv |
An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor
|
BRPI0408116B1
(pt)
|
2003-03-05 |
2022-09-20 |
Halozyme, Inc |
Polipeptídeos de hialuronidase solúveis conjugados a polímero, composições farmacêuticas compreendendo polipeptídeos ph20 solúveis, seus usos e processo de preparação, e ácidos nucléicos que codificam polipeptídeos de hialuronidase solúveis
|
MXPA05011078A
(es)
|
2003-04-15 |
2006-01-24 |
Astellas Pharma Inc |
Bromuro y sus cristales.
|
UA101945C2
(uk)
|
2003-05-30 |
2013-05-27 |
Дженентек, Инк. |
Лікування злоякісного новоутворення за допомогою бевацизумабу
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
EP1689435A4
(fr)
|
2003-10-22 |
2007-10-03 |
Univ Rochester |
Antiserum anti-thymocyte et son utilisation pour declencher l'apoptose des cellules b
|
KR101128777B1
(ko)
|
2003-11-04 |
2012-04-13 |
조마 테크놀로지 리미티드 |
다발성 골수종을 치료하기 위한 길항제 항-cd40단클론성 항체의 용도
|
JP4712724B2
(ja)
|
2003-12-23 |
2011-06-29 |
クルセル ホランド ベー ヴェー |
CD1aに対するヒト結合分子
|
CA2555185C
(fr)
|
2004-02-06 |
2020-03-24 |
Morphosys Ag |
Anticorps humains anti-cd38 et utilisations de ceux-ci
|
BRPI0507489A
(pt)
|
2004-02-06 |
2007-07-10 |
Morphosys Ag |
anticorpos humanos de anti-cd38 e para os seus usos
|
EA015584B1
(ru)
|
2005-03-23 |
2011-10-31 |
Генмаб А/С |
Антитело к cd38 человека и его применение
|
CN109485727A
(zh)
|
2005-05-09 |
2019-03-19 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
US20090123950A1
(en)
|
2005-05-24 |
2009-05-14 |
Morphosys Ag |
Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
|
AU2006301446B2
(en)
|
2005-10-12 |
2012-06-07 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
|
US20090304687A1
(en)
|
2005-12-09 |
2009-12-10 |
Seattle Genetics , Inc. |
Methods of using cd40 binding agents
|
PL2049109T3
(pl)
|
2006-08-02 |
2016-05-31 |
Sunesis Pharmaceuticals Inc |
Skojarzone zastosowanie kwasu (+)-1,4-dihydro-7-[(3s,4s)-3-metoksy-4-(metyloamino)-1-pirolidynylo]-4-okso-1-(2-tiazolilo)-1,8-naftyrydyno-3-karboksylowego i cytarabiny (Ara-C) do leczenia białaczki
|
WO2008073160A2
(fr)
|
2006-08-17 |
2008-06-19 |
The Trustees Of Columbia University In The City Of New York |
Procédés de conversion ou d'induction d'une immunité protectrice
|
CA2664740C
(fr)
|
2006-09-26 |
2021-11-16 |
Genmab A/S |
Traitement combine de tumeurs exprimant la cd38
|
EP1914242A1
(fr)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Nouveau anticorps Anti-CD38 pour le traitement du cancer
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
US7618992B2
(en)
|
2006-12-29 |
2009-11-17 |
Astellas Pharma Inc. |
Method of treating cancer by co-administration of anticancer agents
|
CA2681743A1
(fr)
|
2007-03-22 |
2008-09-25 |
Imclone Llc |
Formulations d'anticorps stables
|
JP5456658B2
(ja)
|
2007-03-30 |
2014-04-02 |
メディミューン,エルエルシー |
抗体製剤
|
US20100330081A1
(en)
|
2007-06-01 |
2010-12-30 |
Biogen Idec Ma Inc. |
Cripto binding molecules
|
ES2437327T3
(es)
|
2007-06-18 |
2014-01-10 |
Merck Sharp & Dohme B.V. |
Anticuerpos para el receptor PD-1 humano de muerte programada
|
US20090076249A1
(en)
|
2007-09-19 |
2009-03-19 |
Michel De Weers |
Antibodies against CD38 for treatment of multiple myeloma
|
US8748356B2
(en)
|
2007-10-19 |
2014-06-10 |
Janssen Biotech, Inc. |
Methods for use in human-adapting monoclonal antibodies
|
AU2008323815B2
(en)
|
2007-11-09 |
2013-09-19 |
Novartis Ag |
Uses of anti-CD40 antibodies
|
US8440199B2
(en)
|
2007-12-12 |
2013-05-14 |
Imperial Innovations Limited |
Methods for mobilizing mesenchymal stem cells in a patient
|
JP2011507519A
(ja)
|
2007-12-19 |
2011-03-10 |
セントコア・オーソ・バイオテツク・インコーポレーテツド |
pIX又はpVIIへの融合を介したヒトデノボpIXファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
|
CA2717803A1
(fr)
|
2008-03-03 |
2009-09-11 |
Dyax Corp. |
Proteines de liaison a la metalloproteinase 9 et a la metalloproteinase 2
|
KR101489028B1
(ko)
|
2008-03-06 |
2015-02-03 |
할로자임, 아이엔씨 |
가용성 히알루로니다아제의 대규모 제조
|
TWI532498B
(zh)
|
2008-03-17 |
2016-05-11 |
巴克斯特保健公司 |
供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
|
US20090246197A1
(en)
|
2008-03-25 |
2009-10-01 |
Charles Dumontet |
Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)
|
WO2009128917A2
(fr)
|
2008-04-14 |
2009-10-22 |
Halozyme, Inc. |
Hyaluronidases modifiées et utilisations pour traiter des maladies et des pathologies associées à l'acide hyaluronique
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
RS58827B1
(sr)
|
2008-11-07 |
2019-07-31 |
Amgen Res Munich Gmbh |
Tretiranje akutne limfoblastne leukemije
|
EP2191840A1
(fr)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et melphalan
|
EP2191842A1
(fr)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine
|
EP2191841A1
(fr)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et vincristine
|
EP2191843A1
(fr)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cyclophosphamide
|
CA2761940C
(fr)
|
2009-05-14 |
2018-04-10 |
Ambit Biosciences Corporation |
Composition pharmaceutique pulverisee a sec renfermant du n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidaze[2,1-b][1,3]benzothiazol-2-yl]phenyl}uree
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
JP5734985B2
(ja)
|
2009-09-17 |
2015-06-17 |
バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA |
ヒアルロニダーゼおよび免疫グロブリンの安定な共製剤およびそれらの使用方法
|
US9096877B2
(en)
|
2009-10-07 |
2015-08-04 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
EP2327725A1
(fr)
|
2009-11-26 |
2011-06-01 |
InflaRx GmbH |
Groupes caractéristiques à liaison anti-C5a avec une activité à blocage élevé
|
EP2542221A4
(fr)
|
2010-03-01 |
2013-10-23 |
Cytodyn Inc |
Formulations concentrées de protéine et leurs utilisations
|
GB201003701D0
(en)
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
WO2011121588A1
(fr)
|
2010-03-29 |
2011-10-06 |
Ben Gurion University Of The Negev Research And Development Authority |
Procédé et système de détection et de surveillance d'un cancer hématologique
|
WO2011154453A1
(fr)
|
2010-06-09 |
2011-12-15 |
Genmab A/S |
Anticorps dirigés contre le cd38 humain
|
MX350540B
(es)
|
2010-09-27 |
2017-09-08 |
Morphosys Ag |
Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl.
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
CL2013001944A1
(es)
|
2010-12-30 |
2014-09-12 |
Takeda Pharmaceutical |
Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune.
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
CA2830516C
(fr)
|
2011-03-23 |
2017-01-24 |
Amgen Inc. |
Doubles inhibiteurs tricycliques fusionnes de cdk 4/6 et de flt3
|
WO2012136732A1
(fr)
*
|
2011-04-08 |
2012-10-11 |
Ab Science |
Traitement du myélome multiple au moyen de mastinib
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
EP2561868A1
(fr)
|
2011-08-24 |
2013-02-27 |
Anton Bernhard Van Oosten |
Compositions pharmaceutiques comportant de l'hydroxychloroquine (HCQ), curcuma, pipérine/BioPérine et utilisations associées dans le domaine médical
|
EP2747571A4
(fr)
|
2011-08-24 |
2015-05-27 |
David Kerr |
Chimiothérapie combinée faiblement dosée
|
KR102037541B1
(ko)
|
2011-10-28 |
2019-10-29 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
폴리펩티드 구축물 및 이의 용도
|
WO2013083140A1
(fr)
|
2011-12-07 |
2013-06-13 |
N.V. Nutricia |
Peptides de bêta-lactoglobuline pour traiter une allergie aux protéines du lait de vache
|
EP3130347B1
(fr)
|
2011-12-30 |
2019-09-18 |
Halozyme, Inc. |
Variants polypeptidiques ph20, formulations et utilisations de ceux-ci
|
CA2866692A1
(fr)
|
2012-03-07 |
2013-07-11 |
Cadila Healthcare Limited |
Formulations empechant la formation d'agregats d'anticorps
|
US9913822B2
(en)
|
2012-04-04 |
2018-03-13 |
Halozyme, Inc. |
Combination therapy with an anti-hyaluronan agent and therapeutic agent
|
WO2013173223A1
(fr)
|
2012-05-15 |
2013-11-21 |
Bristol-Myers Squibb Company |
Immunothérapie anticancéreuse par rupture de la signalisation pd-1/pd-l1
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
EP2900232B1
(fr)
|
2012-09-25 |
2017-11-15 |
MorphoSys AG |
Combinaisons et leurs utilisations
|
US9486547B2
(en)
|
2012-11-05 |
2016-11-08 |
Morphosys Ag |
Radiolabelled antibody and uses thereof
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
EP2934585B1
(fr)
|
2012-12-21 |
2018-06-13 |
Seattle Genetics, Inc. |
Anticorps anti-ntb-a et compositions et procédés associés
|
WO2014142220A1
(fr)
|
2013-03-13 |
2014-09-18 |
アステラス製薬株式会社 |
Agent antitumoral
|
US20140271644A1
(en)
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Combination/adjuvant therapy for wt-1-positive disease
|
PT2992013T
(pt)
|
2013-04-29 |
2020-03-05 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado
|
US20140356318A1
(en)
|
2013-05-28 |
2014-12-04 |
Israel Barken |
Adoptive cell therapy with specific regulatory lymphocytes
|
CA2919513A1
(fr)
|
2013-07-15 |
2015-01-22 |
Matthew J. Goldstein |
Utilisations medicales d'agonistes de cd38
|
WO2015067570A2
(fr)
|
2013-11-06 |
2015-05-14 |
Boehringer Ingelheim International Gmbh |
Combinaisons pharmaceutiques comprenant des anticorps cd33 et des agents de déméthylation
|
EP3105317B1
(fr)
|
2014-02-14 |
2018-09-19 |
Cellectis |
Cellules destinées à l'immunothérapie modifiées pour cibler un antigène présent à la fois sur les cellules immunitaires et les cellules pathologiques
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
US10106620B2
(en)
|
2014-06-16 |
2018-10-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells
|
WO2015195555A1
(fr)
|
2014-06-16 |
2015-12-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Blocage de cd38 à l'aide d'anticorps anti-cd38 conjugué à la protéine g pour protéger des cellules nk
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
EA035098B1
(ru)
|
2014-07-31 |
2020-04-27 |
Санофи |
Способ лечения рецидивирующей и/или рефрактерной множественной миеломы
|
PE20170676A1
(es)
|
2014-09-09 |
2017-05-22 |
Janssen Biotech Inc |
Terapias de combinacion con anticuerpos anti-cd38
|
BR112017011749A2
(pt)
|
2014-12-04 |
2018-05-15 |
Janssen Biotech Inc |
anticorpos anti-cd38 para o tratamento de leucemia mieloide aguda
|
MA41555A
(fr)
|
2015-02-17 |
2017-12-26 |
Millennium Pharm Inc |
Polythérapie pour le traitement du cancer
|
EA201792546A1
(ru)
|
2015-05-20 |
2018-04-30 |
Янссен Байотек, Инк. |
Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
|
CN107708734B
(zh)
|
2015-06-22 |
2022-01-11 |
詹森生物科技公司 |
用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
MY193727A
(en)
|
2015-06-24 |
2022-10-27 |
Janssen Biotech Inc |
Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
|
EA201890159A1
(ru)
|
2015-06-29 |
2018-11-30 |
АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи |
СПОСОБЫ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКОГО ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ С ПОМОЩЬЮ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
|
PT3827845T
(pt)
|
2015-11-03 |
2022-07-08 |
Janssen Biotech Inc |
Formulações subcutâneas de anticorpos anti-cd38 e suas utilizações
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
US20170121417A1
(en)
|
2015-11-03 |
2017-05-04 |
Janssen Biotech, Inc. |
Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
|
WO2018002181A1
(fr)
|
2016-06-28 |
2018-01-04 |
Umc Utrecht Holding B.V. |
Traitement de maladies médiées par l'ige avec des anticorps qui se lient spécifiquement à cd38
|
US20180117150A1
(en)
*
|
2016-11-01 |
2018-05-03 |
Janssen Biotech, Inc. |
Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
|
US11618787B2
(en)
|
2017-10-31 |
2023-04-04 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
CN112154156A
(zh)
|
2018-03-28 |
2020-12-29 |
武田药品工业株式会社 |
抗cd38抗体的皮下给药
|
US20190298827A1
(en)
|
2018-04-03 |
2019-10-03 |
Janssen Biotech, Inc. |
Methods of Treating Multiple Myeloma
|
WO2020081881A2
(fr)
|
2018-10-17 |
2020-04-23 |
Janssen Biotech, Inc. |
Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
|
JP2022523372A
(ja)
|
2019-02-22 |
2022-04-22 |
ヤンセン バイオテツク,インコーポレーテツド |
Cd38に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法
|
US20200330593A1
(en)
|
2019-03-28 |
2020-10-22 |
Janssen Biotech, Inc. |
Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone
|
US20200316197A1
(en)
|
2019-03-28 |
2020-10-08 |
Janssen Biotech, Inc. |
Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
|
US20200308284A1
(en)
|
2019-03-28 |
2020-10-01 |
Janssen Biotech, Inc. |
Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone
|
WO2020194241A1
(fr)
|
2019-03-28 |
2020-10-01 |
Janssen Biotech, Inc. |
Compositions pharmaceutiques sous-cutanées cliniquement prouvées comprenant des anticorps anti-cd38 et leurs utilisations
|
US20200308296A1
(en)
|
2019-03-28 |
2020-10-01 |
Janssen Biotech, Inc. |
Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
|
US20200392242A1
(en)
|
2019-04-19 |
2020-12-17 |
Janssen Biotech, Inc. |
Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
|
US20200397896A1
(en)
|
2019-04-19 |
2020-12-24 |
Janssen Biotech, Inc. |
Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
|
US20200405854A1
(en)
|
2019-04-19 |
2020-12-31 |
Janssen Biotech, Inc. |
Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
|
US20220275090A1
(en)
|
2021-02-22 |
2022-09-01 |
Janssen Biotech, Inc. |
Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
|